Siemens SARS-CoV-2 testing portfolio detects omicron variant
Dec. 15, 2021—Siemens Healthineers has announced that the company’s SARS-CoV-2 tests are designed to detect the SARS-CoV-2 omicron variant.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Seegene unveils PCR test that IDs omicron, VOCs in one tube
Dec. 13, 2021—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only.
Roche AI-based digital pathology algorithms for breast cancer
Dec. 9, 2021—Roche announced the launch of three research use only automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2) image analysis for breast cancer.
SeptiCyte Rapid receives 510(k) clearance
Dec. 3, 2021—Biocartis announced that the FDA granted 510(k) clearance for its SeptiCyte Rapid test, which was developed under partnership with Immunexpress.
Olympus’ first results of AI-based Dx tool for gastric cancer
Dec. 1, 2021–Results of Olympus’ ongoing joint research program to create an AI-based pathology diagnostic tool were announced at the Japan Society of Digital Pathology Study annual meeting.
FDA approves of QuantiFeron-TB Gold Plus on Liaison XS
Nov. 29, 2021—Qiagen announced that the FDA has approved the Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin’s automated Liaison XS platform.
Bio-Rad adds SARS-CoV-2 S gene delta-kappa variants control
Nov. 24, 2021—Bio-Rad Laboratories has launched its Exact Diagnostics SARS-CoV-2 S Gene Delta-Kappa Variants Control for research testing. The control includes lineages B.1.617.1, B.1.617.2 (AY sublineages), and B.1.617.3.
Microbix expands pandemic test controls portfolio
Nov. 22, 2021—Microbix Biosystems has expanded its portfolio of Quality Assessment Products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.
Cobas 5800 molecular Dx system launched in CE markets
Nov. 18, 2021—Roche launched its Cobas 5800 system in countries accepting the CE mark.
LumiraDx’s COVID-19 antigen test gets expanded EUA
Nov. 5, 2021—LumiraDx announced that the FDA’s emergency use authorization for its SARS-CoV-2 antigen test has been expanded to include screening of asymptomatic individuals.